Skip to content
Companies

Oncotelic Therapeutics

Antisense RNA drugs for cancer and viral disease

Raised to date

$987K

of $13.2M offered across 2 Form D filings

Still open
$12.2M
Investors
4
Last filed
Jul 22, 2026

About

Oncotelic Therapeutics, Inc. is a publicly traded, clinical-stage biotechnology company developing RNA therapeutics and small-molecule drugs for immuno-oncology and virology. The company's primary focus is on advancing its lead candidate, OT-101, which targets the TGF-β pathway to treat solid tumors and severe viral diseases. Oncotelic also leverages a proprietary AI platform to support its research and development efforts.

The company's strategy integrates a first-in-class TGF-β antisense RNA therapeutic (OT-101) with an AI-augmented research platform (PDAOAI) to accelerate the development of precision oncology treatments.

Funding

$12.5M, first sold Dec 2025$275K sold$12.2M still openDec 2025Jun 2026
Now
  • EquityFiled Jul 22, 2026Form D
    $712K/ $712K
  • EquityFiled Dec 11, 2025Form D
    $275K/ $12.5M

Product

OT-101 (TGF-β antisense)

RNA Therapeutic

OT-101 is a lead clinical-stage antisense RNA therapeutic that targets and inhibits the production of TGF-β2, a cytokine that suppresses the immune system within the tumor microenvironment. Initially developed for solid tumors like high-grade glioma, it is also being investigated as a host-directed therapy for severe viral infections, including COVID-19, by modulating a patient's immune response to the pathogen.

  • Antisense RNA mechanism specifically targeting TGF-β2.
  • Designed to reactivate anti-tumor immunity by relieving immune suppression.
  • Potential application in both oncology as a monotherapy or combination agent and in virology as a host-directed therapy.

Built for

The primary targets are patients with specific malignancies, alongside potential biopharmaceutical partners for co-development or licensing agreements.

People on file